BOC-D-alanine, also written Boc-D-alanine and cataloged as Boc-D-Ala-OH, is the N-(tert-butoxycarbonyl) derivative of D-alanine in free-acid form. The product identity is defined by CAS registry number 7764-95-6, molecular formula C₈H₁₅NO₄, average molecular weight 189.21 g·mol⁻¹, and monoisotopic mass 189.1001 Da. The structural descriptor is the practical model designation because no unified industrial model code is maintained across suppliers. The Boc group occupies the α-amino position, leaving the C-terminal carboxylic acid available for activation; the α-carbon retains the D absolute configuration. The product is supplied as a white to off-white crystalline solid, soluble in DMF, DMSO, methanol and dichloromethane, and only sparingly soluble in water. It is not a salt, so no counter-ion correction is required in mass balance calculations. The free acid differs from Boc-D-alanine methyl ester and from the dicyclohexylammonium salt, which have different CAS registries and require molar corrections if substituted.

Boc-D-alanine is the enantiomeric counterpart of Boc-L-alanine. Both have the same molecular formula and the same average molecular weight, but opposite optical rotation and opposite C_α stereochemistry. The D-isomer is introduced when the target peptide requires a D-residue, such as the D-Ala-D-Ala terminus recognized by vancomycin or stereochemically constrained peptidomimetics. The L-isomer in the same sequence produces a diastereomeric target with altered recognition and stability. The racemic form, Boc-DL-alanine, is not a substitute in enantiopure synthesis because it generates diastereomeric mixtures. These differences are amplified in automated peptide synthesis because a single stereochemical inversion at one residue can shift the retention time of the desired peptide and complicate preparative purification.

How Is Boc-D-Alanine Characterized Against L-Alanine Contamination?

Release testing is designed around the fact that D- and L-isomers have identical molecular weight and cannot be distinguished by ordinary reversed-phase HPLC. A representative specification set is shown in Table 1. Optical rotation is used as a rapid lot-to-lot indicator, but chiral HPLC is the decisive method for enantiomeric purity. Water content is controlled because retained moisture can reduce the apparent coupling yield by hydrolyzing activated intermediates.

The chiral HPLC method generally uses a polysaccharide-based column and an acid-modified organic/aqueous mobile phase; the enantiomeric excess is calculated as 100×(A_D−A_L)/(A_D+A_L). Where direct chiral HPLC is not available, the material is deprotected to D-alanine and derivatized with Marfey’s reagent; the resulting diastereomers are resolved on a standard C₁₈ column. A D/L ratio below 99.0:1.0 is generally rejected for pharmaceutical peptide assembly, because the resulting diastereomer may co-elute with the target peptide and escape conventional UV detection.

Residual solvents are controlled to ICH Q3C class-specific limits. Methanol and ethyl acetate are common crystallization residuals and are reported on the certificate of analysis when detected. The product is not prepared as an aqueous solution; therefore, bioburden is not routinely included in the release panel unless the receiving process requires it.

Solid-Phase Peptide Synthesis Demands Control of Carbodiimide Activation

Boc-D-alanine is used in Boc/benzyl solid-phase peptide synthesis on 0.5–1.0 mmol/g aminomethyl or PAM resin. In a DIC/HOBt protocol, 1.0 equiv Boc-D-alanine is preactivated with 1.0–1.05 equiv HOBt monohydrate, 1.0–1.05 equiv DIC, and 1.1–1.2 equiv N-methylmorpholine in anhydrous DMF or NMP at 0–4 °C for 10–15 min. The reaction is then transferred to the resin. Preactivation beyond 30 min at 20 °C increases oxazolone formation and raises the likelihood of C_α enantiomerization. Coupling concentration is held at 0.1–0.2 M; operation above 0.3 M accelerates symmetrical anhydride formation and can degrade chiral integrity. DMF is dried to ≤0.05% water by Karl Fischer titration, because water at 0.1% or above consumes DIC and lowers active HOBt ester concentration.

If the sequence requires uranium/aminium activation, HATU is used at 0.98–1.0 equiv with 2.0–2.5 equiv DIPEA at the same low-temperature short-activation window. DIPEA is stronger than N-methylmorpholine and can increase racemization if the carboxylate is over-activated. Ninhydrin or chloranil monitoring after 2 h confirms amine depletion; a persistent positive ninhydrin test requires a second coupling with 0.5 equiv freshly activated acid. Final Boc removal is carried out with 95:2.5:2.5 TFA:triisopropylsilane:water for 30–60 min at 20–25 °C. Extended TFA exposure above 3 h is unnecessary and increases tert-butyl cation side reactions with electron-rich side chains.

For automated synthesizers, the Boc-D-alanine pentafluorophenyl ester may be used as an isolated active ester. It is applied at 0.1 M in DMF with 1.0 equiv amine and 1.0 equiv HOBt at 20 °C, reducing the coupling cycle to approximately 30 min. The active ester is more sensitive to hydrolysis than in situ generated HOBt ester; therefore, solvent moisture must remain below 0.05% and the solid ester is stored under nitrogen.

For solution-phase routes, Boc-D-alanine is frequently activated as a mixed anhydride. In a representative procedure, the acid is dissolved in anhydrous THF or dichloromethane, 1.0 equiv N-methylmorpholine is added at −15 °C, and 1.0 equiv isobutyl chloroformate is introduced over 5–10 min. The mixed anhydride is allowed to form for 5–15 min before the amine component is added. Above 0 °C, the mixed anhydride can disproportionate to the symmetrical anhydride and reduce chiral selectivity. This route is used for the preparation of Boc-D-Ala-D-Ala-OMe from D-alanine methyl ester hydrochloride, followed by methyl ester hydrolysis and Boc cleavage to obtain D-Ala-D-Ala for antibiotic-binding or peptidoglycan studies.

Orthogonal Protection Chemistry and Comparative Deprotection Profiles

The choice among Boc-D-alanine, Fmoc-D-alanine, and Cbz-D-alanine is determined by the global deprotection scheme rather than by the D-alanine residue itself. Table 2 compares the relevant properties. The protecting group does not alter the D-configuration, but it changes the conditions that can be used elsewhere in the sequence.

Boc-D-alanine is selected when the final cleavage uses HF or TFA and when side chains are protected as benzyl or cyclohexyl groups. Fmoc-D-alanine is preferred when piperidine-mediated deprotection is required and acid contact must be minimized. Cbz-D-alanine is used where hydrogenation is acceptable and orthogonal Boc or Fmoc chemistry operates in parallel. Substituting these reagents without adjusting the route is a common source of failed syntheses: piperidine does not remove Boc, and hydrogenolysis does not remove Fmoc, so the protecting group remains attached at the wrong stage if the route is not re-designed. In an Fmoc route, Boc-D-alanine can serve as an N-terminal capping group because the final TFA cleavage removes the Boc group after resin-bound assembly, but it cannot be used as an internal residue under standard Fmoc deprotection because piperidine does not remove it.

On a 10–100 mmol peptide synthesizer with overhead stirring, the limiting variable is often the DMF feed rather than the intrinsic reactivity of the protected amino acid. Karl Fischer titration should record ≤0.05% water at the start of the campaign; if the value is above 0.1%, DIC consumption and active ester loss become measurable. Agitation must maintain uniform suspension of aminomethyl resin beads without high-shear fracture. Published multi-kilogram campaign data for this specific protected amino acid is limited; therefore, the 0.1–0.2 M coupling parameters established in small vessels require re-validation against mixing power per unit volume and bed temperature in the larger reactor. The release method should provide chiral HPLC resolution Rs ≥2.0; methods with Rs <1.5 under-report L-isomer contamination.

When Enantiomeric Drift Exceeds Acceptance Limits

If the final peptide or the released D-amino acid shows D/L interchange above the acceptance limit, the first audit target is the coupling activation protocol, not the starting reagent. The peptide is hydrolyzed and analyzed by chiral HPLC or Marfey’s derivatization; a typical acceptance threshold is ≤1.0% L-isomer. Above this threshold, the preactivation time is reduced from 30 min to 10 min, the reaction temperature is lowered from 20 °C to 0–4 °C, and DIPEA is replaced with N-methylmorpholine. The weaker base slows carboxylate formation and reduces oxazolone-mediated racemization. A reference dipeptide such as Boc-D-Ala-Gly-OH is then carried through the same protocol, hydrolyzed, and derivatized to confirm the corrected method. If the D/L ratio remains above the limit, the incoming protected amino acid is re-tested by chiral HPLC and the storage history is reviewed.

Storage of the solid is 2–8 °C in a tightly closed container under inert gas. The material is packaged in amber glass or aluminum-laminated polyethylene bags under nitrogen, with desiccant packs when low water content must be maintained. Exposure to relative humidity above 60% can hydrate the powder and reduce assay. Open handling in humid production areas is kept below 30 min unless the material is held under dry nitrogen. For long-duration storage involving repeated opening, −20 °C may be used, but temperature cycling is avoided because condensation can introduce moisture. The product is not combined with strong acid except in intended Boc deprotection; prolonged contact with neat TFA or HCl/dioxane removes the protecting group. Storage in contact with free-amine-containing scavengers is avoided, because unintended salt formation changes downstream stoichiometry and complicates dissolution.